August 12, 2014
Endo Pharmaceuticals Inc. and Impax Laboratories Inc. were hit with a putative antitrust class action in an Illinois federal court Monday, in which a direct purchaser accuses Endo of paying Impax more than $112 million to delay a generic version of Endo's patented Opana ER painkiller.